A new preclinical study reveals that KRAS-mutant gastric adenocarcinoma fosters a TGF-beta-dependent immunosuppressive tumour ...

Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to ...

This bet comes amid the strong industry buzz around the approval of Revolution Medicines’ OS-doubling pancreatic cancer ...

SAN DIEGO -- Treatment with investigational elisrasib, a next-generation KRAS G12C inhibitor, showed efficacy in patients with advanced non-small cell lung cancer (NSCLC) with and without previous ...

Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015. Merck entered into an ...

A study led by University of Cincinnati Cancer Center researchers sheds new light on how pancreatic cancer cells resist treatment and points to potential new combination therapies to make treatments ...

Fast track designation targets a post–immunotherapy and post-platinum KRAS G12C–mutant NSCLC population, enabling closer FDA ...

G12C therapies broaden patient reach, while biomarker-led combinations and US-focused launches can unlock unmet demand and strengthen competitive positioning.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ...

Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant ...

According to Asfar Azmi, PhD, results from the study showed that the PCNA inhibitor AOH1996 was synergistic with KRAS inhibitors of all classes. The combination of the first-in-class PCNA inhibitor ...